332109-84-9

Upstream product

• 220461-97-2 (4-bromo-2-chloro-phenyl)-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)-methanone 
• 1066-54-2 trimethylsilylacetylene 

Downstream Products

• 332109-66-7 1-[4-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-3-chlorophenyl]-ethanone 
• 220462-20-4 [2-chloro-4-(3-methyl-4-ethynyl-phenyl)](5H,11H-pyrrolo[2,1-c][1,4]-benzodiazepin-10-yl)-methanone 

Relevant academic research and scientific papers

Vasopressin agonist formulation and process

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having the general structure: and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.